GlassScriptPhysician profile
Wendy C Daly
NPI 1043339419
$3,734.02
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,748 · 2020: $321 · 2021: $577 · 2022: $88.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,343.53 | 2019-2021 | |
| Seqirus USA INC | $1,245.34 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.35 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $177.10 | 2021 | |
| Genentech USA, INC. | $112.81 | 2019 | |
| Sanofi Pasteur INC. | $103.64 | 2019-2022 | |
| Neos Therapeutics, LP | $85.87 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $83.68 | 2019-2022 | |
| Sobi, INC | $81.14 | 2019-2021 | |
| Adlon Therapeutics L.P. | $68.22 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $52.61 | 2020-2021 | |
| Kaleo, INC. | $43.55 | 2019 | |
| Tris Pharma INC | $41.29 | 2019-2021 | |
| Shire North American Group INC | $35.51 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.99 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $15.40 | 2019 | |
| Pfizer INC. | $14.15 | 2019 | |
| Mission Pharmacal Company | $10.84 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.